Efficacy of montelukast sodium chewable tablets combined with inhaled budesonide in treating pediatric asthma and its effect on inflammatory factors.

Yu Zhang, Hai Wang
{"title":"Efficacy of montelukast sodium chewable tablets combined with inhaled budesonide in treating pediatric asthma and its effect on inflammatory factors.","authors":"Yu Zhang, Hai Wang","doi":"10.1691/ph.2019.9582","DOIUrl":null,"url":null,"abstract":"The aim of this study was to explore the clinical effect of montelukast sodium chewable tablets combined with inhaled budesonide in the treatment of pediatric asthma and its influence on inflammatory factors. One hundred and thirty-five asthmatic children were randomly divided into montelukast sodium group, budesonide group and combined group. Clinical symptoms, lung function, inflammatory factors and immune related indices of patients in each group were observed and recorded. After treatment, the times to disappearance of wheezes, dyspnea, asthma and hospital stay in the combined group were significantly shorter than those in the single-drug group (all p < 0.001). Forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), peak expiratory flow (PEF) were significantly higher than those before treatment, and in the combined group value were significantly higher than in the single-drug group in the same period (all p < 0.001). Tumor necrosis factor-α (TNF-α), interleukin-4 (IL-4), IL-8 and hypersensitive C-reactive protein (hs-CRP) were significantly lower than before treatment, and the combined group was significantly lower than the single-drug group in the same period (all p < 0.05). The number of CD4+ and CD3+ cells in the combined group was significantly higher than that in the single-drug group, while the number of CD8 + cells and the expression level of immune globulin E (IgE) were significantly lower (all p < 0.05). There was no difference in the incidence of adverse reactions between the groups during treatment (p > 0.05). Six months after treatment, the incidence of asthma in the combined group was significantly lower than that in the single-drug group (both p < 0.05). Montelukast sodium chewable tablets combined with inhaled budesonide can shorten the discomfort duration of asthmatic children and help them restore lung function. Moreover, it reduces the level of inflammatory factors and increases the resistance of children, which is worthy of further promotion and application.","PeriodicalId":86039,"journal":{"name":"Die Pharmazie. Beihefte","volume":"22 1","pages":"694-697"},"PeriodicalIF":0.0000,"publicationDate":"2019-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Die Pharmazie. Beihefte","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1691/ph.2019.9582","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 10

Abstract

The aim of this study was to explore the clinical effect of montelukast sodium chewable tablets combined with inhaled budesonide in the treatment of pediatric asthma and its influence on inflammatory factors. One hundred and thirty-five asthmatic children were randomly divided into montelukast sodium group, budesonide group and combined group. Clinical symptoms, lung function, inflammatory factors and immune related indices of patients in each group were observed and recorded. After treatment, the times to disappearance of wheezes, dyspnea, asthma and hospital stay in the combined group were significantly shorter than those in the single-drug group (all p < 0.001). Forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), peak expiratory flow (PEF) were significantly higher than those before treatment, and in the combined group value were significantly higher than in the single-drug group in the same period (all p < 0.001). Tumor necrosis factor-α (TNF-α), interleukin-4 (IL-4), IL-8 and hypersensitive C-reactive protein (hs-CRP) were significantly lower than before treatment, and the combined group was significantly lower than the single-drug group in the same period (all p < 0.05). The number of CD4+ and CD3+ cells in the combined group was significantly higher than that in the single-drug group, while the number of CD8 + cells and the expression level of immune globulin E (IgE) were significantly lower (all p < 0.05). There was no difference in the incidence of adverse reactions between the groups during treatment (p > 0.05). Six months after treatment, the incidence of asthma in the combined group was significantly lower than that in the single-drug group (both p < 0.05). Montelukast sodium chewable tablets combined with inhaled budesonide can shorten the discomfort duration of asthmatic children and help them restore lung function. Moreover, it reduces the level of inflammatory factors and increases the resistance of children, which is worthy of further promotion and application.
孟鲁司特钠咀嚼片联合吸入布地奈德治疗小儿哮喘的疗效及对炎症因子的影响。
本研究旨在探讨孟鲁司特钠咀嚼片联合吸入布地奈德治疗小儿哮喘的临床疗效及对炎症因子的影响。135例哮喘患儿随机分为孟鲁司特钠组、布地奈德组和联合组。观察并记录各组患者的临床症状、肺功能、炎症因子及免疫相关指标。治疗后,联合用药组喘息、呼吸困难、哮喘消失次数及住院时间均显著短于单药组(p < 0.001)。用力肺活量(FVC)、第一秒用力呼气量(FEV1)、呼气峰流量(PEF)均显著高于治疗前,且联合用药组同期均显著高于单药组(p < 0.001)。肿瘤坏死因子-α (TNF-α)、白细胞介素-4 (IL-4)、IL-8、超敏c反应蛋白(hs-CRP)均显著低于治疗前,且同期联合用药组显著低于单药组(均p < 0.05)。联合用药组CD4+、CD3+细胞数量显著高于单药组,CD8 +细胞数量及免疫球蛋白E (IgE)表达水平显著低于单药组(均p < 0.05)。两组患者治疗过程中不良反应发生率比较,差异无统计学意义(p > 0.05)。治疗6个月后,联合用药组哮喘发病率显著低于单药组(p < 0.05)。孟鲁司特钠咀嚼片联合吸入布地奈德可缩短哮喘患儿的不适持续时间,帮助患儿恢复肺功能。而且降低了炎症因子水平,增加了儿童的抵抗力,值得进一步推广应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信